Skip to main content

Hypopara Newsroom




If you want to be in the know about what’s going on at our organization, you’ve come to the right place. Be sure to check back regularly to get our latest news updates.

For U.S. patients receiving NATPARA through the Special Use Program

Over 500 people in 45 States and 24 Countries on 6 Continents!

For a limited time the presentations can be viewed here on the website.

Plans move forward with phase 3 PaTHway trial

The study will be conducted at the National Institutes of Health.

Working closely with physicians and care providers in managing hypoparathyroidism

Ongoing information about the future availability of the prescription parathyroid hormone

Takeda has issued a letter to the hypoparathyroidism community confirming that the COVID-19 pandemic will NOT impact Natpara Special Use Program supply, Special Use Program applications or the development activities in progress that will support Natpara's return to the US market.